Investigating the effects of a probiotic on type 1 diabetes in adults
Evaluation of safety, tolerability and immunological responses to Lactobacillus johnsonii N6.2 supplementation in adults with Diabetes type 1
This study is looking at whether a probiotic called Lactobacillus johnsonii N6.2 is safe and well-tolerated for adults with type 1 diabetes, as it might help balance gut bacteria and possibly prevent the disease in those at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10877670 on NIH RePORTER |
What this research studies
This research evaluates the safety and tolerability of Lactobacillus johnsonii N6.2, a probiotic, in adults with type 1 diabetes. The study builds on previous findings in rodents that suggested this probiotic could reduce the incidence of type 1 diabetes by restoring microbiota balance. Participants will receive the probiotic and be monitored for immune responses and any adverse effects. The ultimate goal is to explore whether this probiotic can help prevent the onset of type 1 diabetes in at-risk individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with type 1 diabetes who are interested in exploring new treatment options.
Not a fit: Patients who do not have type 1 diabetes or those who are not interested in probiotic treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new preventive strategies for type 1 diabetes, potentially improving the quality of life for individuals at risk.
How similar studies have performed: Previous studies have shown promising results with probiotics in animal models, but this research is among the first to evaluate its effects in humans with type 1 diabetes.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Lorca, Graciela L — University of Florida
- Study coordinator: Lorca, Graciela L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.